Spotlight on Schizophrenia
It is still unclear what causes the delusions that characterise a psychosis. However, scientists have found a series of risk genes for schizophrenia which they hope can provide clues to its causes and new cures. The most urgent issue, though, is combating the sharp increase in cardiovascular disease which can shorten patients' lives by 15-20 years.
Prisoner in another world
Prisoner in another world
By taking a closer look at how genes are linked with schizophrenia, scientists hope to understand the causes and find better remedies
"It's worse than being in a nightmare"
"It's worse than being in a nightmare"
Peter Johansson, 55, can clearly distinguish between before and after his schizophrenia diagnosis.
"Treatment halves violent crime"
"Treatment halves violent crime"
Professor Paul Lichtenstein has studied over 82,000 Swedes with a psychiatric diagnosis.
Cell types underlying schizophrenia identified
Cell types underlying schizophrenia identified
Scientists at Karolinska Institutet in Sweden and University of North Carolina, USA, have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development of new therapies to target the condition.
Long-term medication for schizophrenia is safe
Long-term medication for schizophrenia is safe
Researchers at CNS and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia. According to the study, which is published in the scientific journal World Psychiatry, mortality was higher during periods when patients were not on medication than when they were.
Treatable mechanism identified in patients with schizophrenia
Treatable mechanism identified in patients with schizophrenia
For reasons that are unclear, schizophrenia patients have fewer connections between the neurons in the brain. Researchers have now discovered that there is an excessive degradation of connections in the brain of these patients, and that treatment in adolescence with the antibiotic minocycline inhibits the degradation.
Combination therapy might be beneficial in schizophrenia
Combination therapy might be beneficial in schizophrenia
Combining certain types of two antipsychotic agents in the maintenance treatment of schizophrenia is associated with a lower risk of relapse than using monotherapy, according to a new study by KI Professor Jari Tiihonen and coelleagues.
Research network on schizophrenia
Research network on schizophrenia
The Karolinska Schizophrenia Project (KaSP) is a collaboration between researchers from the Department of Clinical Neuroscience and the Department of Physiology and Pharmacology at Karolinska Institutet. Together, the researchers aim at clarifying the role of the brain's immune mechanisms for the etiology and the development of pathophysiology in the disease.